M
María-Vega Catalina
Researcher at Hospital General Universitario Gregorio Marañón
Publications - 52
Citations - 1617
María-Vega Catalina is an academic researcher from Hospital General Universitario Gregorio Marañón. The author has contributed to research in topics: Cirrhosis & Portal venous pressure. The author has an hindex of 18, co-authored 43 publications receiving 1408 citations. Previous affiliations of María-Vega Catalina include Carlos III Health Institute & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era
Cristina Ripoll,Rafael Bañares,Diego Rincón,María-Vega Catalina,Oreste Lo Iacono,Magdalena Salcedo,Gerardo Clemente,O. Nunez,Ana Matilla,Luis-Miguel Molinero +9 more
TL;DR: HVPG has an independent effect on survival in addition to the Model for End‐Stage Liver Disease (MELD) score, and its discriminative ability is not significantly improved.
Journal ArticleDOI
Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure.
Cristina Ripoll,Rafael Bañares,Inmaculada Beceiro,Pedro Menchén,María-Vega Catalina,A. Echenagusia,Fernando Turegano +6 more
TL;DR: The lack of differences between these two treatment alternatives, despite the more advanced age and greater prevalence of heart disease in the embolotherapy group, provides support for future prospective randomized studies aimed to evaluate the role of embol therapy in the management of refractory peptic ulcer bleeding.
Journal ArticleDOI
A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites
TL;DR: In patients with refractory ascites, a better control of ascites by TIPS does not translate into improved survival and worsens encephalopathy.
Journal ArticleDOI
Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis
Agustín Albillos,Rafael Bañares,Mónica González,Cristina Ripoll,Rosario Gonzalez,María-Vega Catalina,Luis-Miguel Molinero +6 more
TL;DR: Current evidence supports the validity of HVPG end points to monitor drug therapy efficacy for variceal bleeding prophylaxis and also provides valuable prognostic information.
Journal ArticleDOI
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS
Jonel Trebicka,Wenyi Gu,Wenyi Gu,Luis Ibáñez-Samaniego,Virginia Hernández-Gea,Carla Pitarch,Elisabet Garcia,Bogdan Procopet,Álvaro Giráldez,Lucio Amitrano,Càndid Villanueva,Dominique Thabut,Gilberto Silva-Junior,Javier Martínez,Joan Genescà,C. Bureau,Elba Llop,Wim Laleman,José María Palazón,José Castellote,Susanag Rodrigues,L.L. Gluud,Carlos Noronha Ferreira,Rafael Ramis Barceló,Nuria Cañete,Manuel Rodríguez,Arnulf Ferlitsch,Jose Luis Mundi,Henning Grønbæk,Manuel Hernández-Guerra,Romano Sassatelli,Alessandra Dell'Era,Marco Senzolo,Juan G. Abraldes,Manuel Romero-Gómez,Alexander Zipprich,Meritxell Casas,Helena Masnou,Massimo Primignani,Emmanuel Weiss,María-Vega Catalina,Hans-Peter Erasmus,Frank Erhard Uschner,Martin Schulz,Maximilian J. Brol,Michael Praktiknjo,Johannes Chang,Aleksander Krag,Frederik Nevens,Jose Luis Calleja,Marie Angèle Robic,Irene Conejo,Agustín Albillos,Marika Rudler,Edilmar Alvarado,Maria Anna Guardascione,Marcel Tantau,Jaime Bosch,Jaime Bosch,Ferran Torres,Marco Pavesi,Juan Carlos García-Pagán,Christian Jansen,Rafael Bañares +63 more
TL;DR: This large multi-center international real-life study identified ACLF as at admission an independent predictor of rebleeding and mortality in AVB and pTIPS may be considered in ACLF patients with AVB, although the presented data need to be independently validated.